FDA-approved
Digestive & weight
Semaglutide
Evidence
FDA approved
Class
GLP-1 receptor agonist
KEY TAKEAWAY
Semaglutide is a GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management. In a large trial of adults with obesity, people taking 2.4 mg weekly lost about 15% of their body weight over 68 weeks, compared with about 2% on placebo.
Written by the Veylo editorial team · Updated
November 2026
What it is
A long-acting copy of the gut hormone GLP-1
Approved for
Type 2 diabetes, chronic weight management and cardiovascular risk reduction in selected adults
Key fact
Lowered body weight by roughly 15% in a 68-week trial
Route
Weekly injection or daily tablet
Evidence strength
FDA approved
Semaglutide is a modified version of the gut hormone GLP-1, engineered to last about a week in the body. It is sold under brand names including Ozempic, Wegovy and Rybelsus.
It activates GLP-1 receptors in the pancreas and brain. That raises insulin release after meals, slows stomach emptying and dampens appetite signals, so most people eat less without feeling as hungry.
The FDA approved semaglutide for type 2 diabetes in 2017 and for chronic weight management in 2021. Approval covers the branded products, not unapproved compounded copies.
Blood sugar control in type 2 diabetes, long-term weight management in adults with obesity or overweight plus a related condition, and lowering cardiovascular risk in selected patients.
Nausea, vomiting, diarrhea and constipation are the most common effects, especially as the dose goes up. Gallbladder problems and pancreatitis are less common. The label carries a boxed warning about thyroid C-cell tumors seen in rodents.
Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989-1002.
Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.